Terence J. Purdon

5.7k total citations · 1 hit paper
41 papers, 3.1k citations indexed

About

Terence J. Purdon is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Terence J. Purdon has authored 41 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 18 papers in Immunology and 11 papers in Molecular Biology. Recurrent topics in Terence J. Purdon's work include CAR-T cell therapy research (40 papers), Immune Cell Function and Interaction (11 papers) and Viral Infectious Diseases and Gene Expression in Insects (8 papers). Terence J. Purdon is often cited by papers focused on CAR-T cell therapy research (40 papers), Immune Cell Function and Interaction (11 papers) and Viral Infectious Diseases and Gene Expression in Insects (8 papers). Terence J. Purdon collaborates with scholars based in United States, Switzerland and Netherlands. Terence J. Purdon's co-authors include Renier J. Brentjens, Mythili Koneru, David R. Spriggs, Oladapo Yeku, Dayenne G. van Leeuwen, Anthony F. Daniyan, Kevin J. Curran, Sarwish Rafiq, Andrea V. Lopez and Pei Wang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Terence J. Purdon

41 papers receiving 3.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

2018 628 citations Sarwish Rafiq, Oladapo Yeku et al. Nature Biotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Terence J. Purdon United States	22	2.9k	1.1k	1.0k	963	837	41	3.1k
Daniel Sommermeyer United States	25	3.4k 1.2×	1.5k 1.3×	1.1k 1.1×	1.2k 1.2×	1.1k 1.3×	39	3.8k
Cindy Delbrook United States	16	2.9k 1.0×	792 0.7×	715 0.7×	760 0.8×	880 1.1×	27	3.3k
Sarwish Rafiq United States	15	2.2k 0.8×	1.1k 1.0×	767 0.8×	916 1.0×	537 0.6×	34	2.8k
Meng-Fen Wu United States	16	2.4k 0.8×	1.0k 0.9×	627 0.6×	815 0.8×	743 0.9×	18	2.9k
Mohamad Hamieh United States	14	3.8k 1.3×	1.5k 1.3×	1.3k 1.3×	1.7k 1.8×	1.2k 1.5×	26	4.6k
Olga Dakhova United States	24	2.4k 0.8×	914 0.8×	712 0.7×	1.1k 1.1×	822 1.0×	40	3.1k
Sjoukje J. C. van der Stegen United States	13	4.1k 1.4×	1.5k 1.4×	1.5k 1.5×	1.7k 1.8×	1.3k 1.6×	18	4.7k
Valentina Hoyos United States	19	2.1k 0.7×	1.0k 0.9×	667 0.7×	838 0.9×	782 0.9×	35	2.6k
Antonio Di Stasi United States	16	2.2k 0.8×	954 0.8×	648 0.6×	887 0.9×	916 1.1×	42	2.8k

Countries citing papers authored by Terence J. Purdon

Since Specialization

Citations

This map shows the geographic impact of Terence J. Purdon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terence J. Purdon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terence J. Purdon more than expected).

Fields of papers citing papers by Terence J. Purdon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Terence J. Purdon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terence J. Purdon. The network helps show where Terence J. Purdon may publish in the future.

Co-authorship network of co-authors of Terence J. Purdon

This figure shows the co-authorship network connecting the top 25 collaborators of Terence J. Purdon. A scholar is included among the top collaborators of Terence J. Purdon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Terence J. Purdon. Terence J. Purdon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Drakes, Dylan J., Sarwish Rafiq, Terence J. Purdon, et al.. (2020). Optimization of T-cell Receptor–Modified T Cells for Cancer Therapy. Cancer Immunology Research. 8(6). 743–755. 24 indexed citations

Larrea, Carlos Fernández de, Mette Stæhr, Andrea V. Lopez, et al.. (2020). Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma. Blood Cancer Discovery. 1(2). 146–154. 147 indexed citations

Song, Mei, Oladapo Yeku, Sarwish Rafiq, et al.. (2020). Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages. Nature Communications. 11(1). 6298–6298. 111 indexed citations

Yeku, Oladapo, Sarwish Rafiq, Mythili Koneru, et al.. (2020). Abstract IA21: MUC16-directed immunotherapy for ovarian cancer. Clinical Cancer Research. 26(13_Supplement). IA21–IA21. 2 indexed citations

Li, Xinghuo, Anthony F. Daniyan, Andrea V. Lopez, Terence J. Purdon, & Renier J. Brentjens. (2020). Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response. Leukemia. 35(2). 506–521. 50 indexed citations

Smith, Eric L., Sham Mailankody, Mette Stæhr, et al.. (2019). BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy. Cancer Immunology Research. 7(7). 1047–1053. 67 indexed citations

Geyer, Mark B., Isabelle Rivière, Brigitte Sénéchal, et al.. (2019). Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. JCI Insight. 4(9). 69 indexed citations

Larrea, Carlos Fernández de, Mette Stæhr, Andrea V. Lopez, et al.. (2019). Optimal Dual-Targeted CAR Construct Simultaneously Targeting Bcma and GPRC5D Prevents Bcma-Escape Driven Relapse in Multiple Myeloma. Blood. 134(Supplement_1). 136–136. 20 indexed citations

Kuhn, Nicholas F., Terence J. Purdon, Dayenne G. van Leeuwen, et al.. (2019). CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response. Cancer Cell. 35(3). 473–488.e6. 187 indexed citations

10.

Rafiq, Sarwish, Oladapo Yeku, Terence J. Purdon, et al.. (2018). Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nature Biotechnology. 36(9). 847–856. 628 indexed citations breakdown →

11.

Santomasso, Bianca, Jae Hong Park, Isabelle Rivière, et al.. (2018). Neurotoxicity Associated with CD19-specific Chimeric Antigen Receptor T cell Therapy for Adult Acute Lymphoblastic Leukemia (B-ALL) (S23.008). Neurology. 90(15_supplement). 3 indexed citations

12.

Avanzi, Mauro P., Oladapo Yeku, Xinghuo Li, et al.. (2018). Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Reports. 23(7). 2130–2141. 268 indexed citations

13.

Geyer, Mark B., Isabelle Rivière, Brigitte Sénéchal, et al.. (2018). Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. Molecular Therapy. 26(8). 1896–1905. 60 indexed citations

14.

Park, Jae Hong, Bianca Santomasso, Isabelle Rivière, et al.. (2017). Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL.. Journal of Clinical Oncology. 35(15_suppl). 7024–7024. 20 indexed citations

15.

Rafiq, Sarwish, Terence J. Purdon, Anthony F. Daniyan, et al.. (2016). Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen. Leukemia. 31(8). 1788–1797. 128 indexed citations

16.

Geyer, Mark B., Jae Hong Park, Isabelle Rivière, et al.. (2016). Updated results: phase I trial of autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy.. Journal of Clinical Oncology. 34(15_suppl). 7526–7526. 5 indexed citations

17.

Curran, Kevin J., Yan Nikhamin, Raymond Yeh, et al.. (2015). Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression. Molecular Therapy. 23(4). 769–778. 188 indexed citations

18.

Koneru, Mythili, et al.. (2015). IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. OncoImmunology. 4(3). e994446–e994446. 361 indexed citations

19.

Park, Jae H., Isabelle Rivière, Xiuyan Wang, et al.. (2014). CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients with Relapsed, Refractory B-Cell ALL. Blood. 124(21). 382–382. 17 indexed citations

20.

Pegram, Hollie J., Terence J. Purdon, Dayenne G. van Leeuwen, et al.. (2014). IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia. 29(2). 415–422. 126 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact